Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

被引：0
|
作者：
Ziccheddu, Bachisio [1 ]
Giannotta, Claudia [2 ]
D'Agostino, Mattia [3 ]
Bertuglia, Giuseppe [3 ]
Saraci, Elona [4 ]
Oliva, Stefania [3 ]
Diamond, Benjamin [1 ]
Bolli, Niccolo [5 ]
Corradini, Paolo [6 ,7 ]
Coffey, David [8 ]
Landgren, Ola [1 ]
Bruno, Benedetto [3 ]
Boccadoro, Mario [3 ]
Massaia, Massimo [9 ]
Maura, Francesco [1 ]
Larocca, Alessandra [3 ]
机构：
[1] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Mol Biotechnol Ctr Guido Tarone, Lab Blood Tumor Immunol, Turin, Italy
[3] Univ Torino, Div Hematol, Myeloma Unit, Azienda Osped Univ Citta Salute & Sci Torino, Turin, Italy
[4] Univ Torino, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[5] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Ematol, Milan, Italy
[6] Univ Milan, Milan, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Pinecrest, FL USA
[9] Santa Croce & Carle Hosp, Div Hematol, Cuneo, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182301
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Aleman, Adolfo
    Zajdman, Ariel Kogan
    Mouhieddine, Tarek
    Upadhyaya, Bhaskar
    Van Oekelen, Oliver
    Lagana, Alessandro
    Grossman, Leah
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Rossi, Adriana
    Richter, Joshua
    Cho, Hearn Jay
    Rodriguez-Valdes, Cesar
    Chari, Ajai
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S41 - S41
  • [2] The Anti-CD38 Antibody Therapy in Multiple Myeloma
    Petrucci, Maria Teresa
    Vozella, Federico
    CELLS, 2019, 8 (12)
  • [3] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
    Saltarella, Ilaria
    Desantis, Vanessa
    Melaccio, Assunta
    Solimando, Antonio Giovanni
    Lamanuzzi, Aurelia
    Ria, Roberto
    Storlazzi, Clelia Tiziana
    Mariggio, Maria Addolorata
    Vacca, Angelo
    Frassanito, Maria Antonia
    CELLS, 2020, 9 (01)
  • [4] Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
    Ziccheddu, Bachisio
    Giannotta, Claudia
    D'Agostino, Mattia
    Bertuglia, Giuseppe
    Saraci, Elona
    Oliva, Stefania
    Genuardi, Elisa
    Papadimitriou, Marios
    Diamond, Benjamin
    Corradini, Paolo
    Coffey, David
    Landgren, Ola
    Bolli, Niccolo
    Bruno, Benedetto
    Boccadoro, Mario
    Massaia, Massimo
    Maura, Francesco
    Larocca, Alessandra
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [5] Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma
    Kastritis, Efstathios
    Fotiou, Despina
    Theodorakakou, Foteini
    Solia, Irene
    Spiliopoulou, Vasiliki
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Kanellias, Nikolaos
    Roussou, Maria
    Migkou, Magdalini
    Eleutherakis-Papaiakovou, Evangelos
    Terpos, Evangelos
    Gavriatopoulou, Maria
    Dimopoulos, Meletios
    BLOOD, 2024, 144 : 7021 - 7022
  • [6] Outcomes of Patients with Relapsed Multiple Myeloma Treated with Pomalidomide, Cyclophosphamide, and Dexamethasone Based on Prior Resistance to Anti-CD38 Monoclonal Antibodies
    Hidalgo-Soto, Marta
    Martin-Rodriguez, Lucia
    Montreal, Eugenia Abella
    Fernandez-Camacho, Inmaculada
    Mesa, Mercedes Gironella
    Gonzalez-Montes, Yolanda
    Lopez, M. Teresa Cibeira
    Dachs, Laura Rosinol
    Perez, Jose Miguel Mateos
    Tovar, Natalia
    Larrea, Carlos Fernandez de
    Rodriguez-Lobato, Luis Gerardo
    BLOOD, 2024, 144 : 6955 - 6956
  • [7] Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma
    Shah, Bhavesh
    Gray, Joy
    Abraham, Ivo
    Chang, Melody
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 170 - 182
  • [8] Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
    Zannetti, Beatrice Anna
    Faini, Angelo Corso
    Massari, Evita
    Geuna, Massimo
    Maffini, Enrico
    Poletti, Giovanni
    Cerchione, Claudio
    Martinelli, Giovanni
    Malavasi, Fabio
    Lanza, Francesco
    CELLS, 2020, 9 (12) : 1 - 13
  • [9] Anti-CD38 nanobodies as theranostic agents for multiple myeloma
    Duray, Elodie
    Lejeune, Margaux
    Dumoulin, Mireille
    D'Huyvetter, Matthias
    Caers, Jo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S28 - S28
  • [10] CLINICAL OUTCOMES ASSOCIATED WITH ANTI-CD38 RETREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REVIEW OF THE LITERATURE
    McNamara, S.
    Chorazy, J.
    Pandey, A.
    Bitetti, J.
    Boytsov, N.
    Purser, M.
    Iheanacho, I.
    VALUE IN HEALTH, 2024, 27 (06) : S31 - S31
12345